Fennec Pharmaceuticals Inc.
FENC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 29.1% | 10.3% | 10.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 94.7% | 90% | 95.7% | 91.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -0% | -26.2% | -8.9% | -11.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5.1% | -32.7% | -13.3% | -25% |
| EPS Diluted | -0.02 | -0.12 | -0.042 | -0.057 |
| % Growth | 83.3% | -184.4% | 26.4% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |